Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo US Bio-TechNSE:INDOUS -1.16%64 ROC (Joel Greenblatt) % is 9.77% as of Mar. 2026, which is 40% below its 10-year median of 16.24. GuruFocus rates NSE:INDOUS with a GF Score™ of 64/100 and a GF Value™ of ₹315.60 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 258 Agriculture companies, Indo US Bio-Tech ranks better than 58.91% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Indo US Bio-Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.77%.
The historical rank and industry rank for Indo US Bio-Tech's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:INDOUS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.46 Med: 16.24 Max: 28.01
Current: 15.38
During the past 13 years, Indo US Bio-Tech's highest ROC (Joel Greenblatt) % was 28.01%. The lowest was 14.46%. And the median was 16.24%.
NSE:INDOUS's ROC (Joel Greenblatt) % is ranked better than 58.91% of 258
companies
in the Agriculture industry
Industry Median: 10.95
vs NSE:INDOUS: 15.38
Indo US Bio-Tech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Indo US Bio-Tech (NSE:INDOUS) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Indo US Bio-Tech ROC (Joel Greenblatt) % Related Terms
Indo US Bio-Tech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: ROC (Joel Greenblatt) % Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech ROC (Joel Greenblatt) % vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's ROC (Joel Greenblatt) % falls into.
Indo US Bio-Tech ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 9.77% mean?
Indo US Bio-Tech (NSE:INDOUS) has a ROC (Joel Greenblatt) % of 9.77% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Indo US Bio-Tech and its competitors. This is 40% below median its historical median of 16.24. Over the past decade, Indo US Bio-Tech's ROC (Joel Greenblatt) % has ranged from 14.46 to 28.01. According to the industry distribution chart, Indo US Bio-Tech ranks #106 out of 258 companies in the Agriculture industry, placing it in the top 41.1%.
Is Indo US Bio-Tech's ROC (Joel Greenblatt) % too high?
Indo US Bio-Tech's current ROC (Joel Greenblatt) % of 9.77% is 40% below median its 10-year median of 16.24. Over the past 10 years, this metric has ranged from a low of 14.46 to a high of 28.01. The Agriculture industry median ROC (Joel Greenblatt) % is 10.95. Indo US Bio-Tech's value of 9.77% is 10.8% below this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #106 out of 258 companies in the Agriculture industry, which is above the industry midpoint. Overall, Indo US Bio-Tech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's ROC (Joel Greenblatt) % compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #106 out of 258 companies for ROC (Joel Greenblatt) %. This puts Indo US Bio-Tech in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 10.95. Indo US Bio-Tech's value of 9.77% is 10.8% below this benchmark. Historically, Indo US Bio-Tech's own ROC (Joel Greenblatt) % has ranged from 14.46 to 28.01 over the past decade. While the company's 10-year median is 16.24 vs. the industry median of 10.95, Indo US Bio-Tech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for an Agriculture company?
The median ROC (Joel Greenblatt) % among Agriculture companies is 10.95, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current ROC (Joel Greenblatt) % of 9.77% is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median ROC (Joel Greenblatt) % is 10.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current ROC (Joel Greenblatt) % is 9.77%, which is 40% below median its own 10-year median of 16.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹315.60, compared to a current price of ₹81.62 — trading 74.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 9.77%, which is 40% below median its 10-year median of 16.24 and 10.8% below the Agriculture industry median of 10.95. Indo US Bio-Tech's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current ROC (Joel Greenblatt) % is 9.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹81.62 is trading 74.1% below its estimated GF Value™ of ₹315.60.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
ROC (Joel Greenblatt) %: 9.77% (40% below median its 10-year median of 16.24)
GF Value™: ₹315.60 vs. price of ₹81.62 (74.1% below fair value)
Industry Position: 10.8% below the Agriculture median (#106 of 258)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
64GF Score
Get the complete analysis for NSE:INDOUS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
